A5014702740- Schizophrenia research and treatment
- Mental Health Treatment and Access
- Bipolar Disorder and Treatment
- Health disparities and outcomes
- Eating Disorders and Behaviors
- Mental Health and Psychiatry
- Regulation of Appetite and Obesity
- Psychiatric care and mental health services
- Innovations in Medical Education
- Diet and metabolism studies
- Family Caregiving in Mental Illness
- Treatment of Major Depression
- Primary Care and Health Outcomes
- Chronic Disease Management Strategies
- Neurotransmitter Receptor Influence on Behavior
- Global Health Workforce Issues
- Sexual function and dysfunction studies
- Child and Adolescent Psychosocial and Emotional Development
- Emergency and Acute Care Studies
- Substance Abuse Treatment and Outcomes
- Receptor Mechanisms and Signaling
- Mental Health and Patient Involvement
- Child and Adolescent Health
- Hormonal and reproductive studies
- Obsessive-Compulsive Spectrum Disorders
University of Wollongong
2016-2025
Illawarra Shoalhaven Local Health District
2012-2023
Creative Commons
2015-2023
Illawarra Health and Medical Research Institute
2011-2022
Wollongong Hospital
2016-2020
Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) purported have antipsychotic properties ameliorate cognitive, symptomatic, brain harms in users. However, this never tested a prolonged administration trial otherwise healthy Here, we report the first study of CBD...
Background. Patients engage in health information-seeking behaviour to maintain their wellbeing and manage chronic diseases such as arthritis. Health literacy allows patients understand available treatments critically appraise information they obtain from a wide range of sources. Aims. To explore how arthritis patients' affects engagement arthritis-focused the selection sources through informal social network. Methods. An exploratory, qualitative study consisting one-on-one semi-structured...
Olanzapine is effective at treating multiple domains of schizophrenia symptoms. However, it induces serious metabolic side effects. Antipsychotic drug’s antagonistic affinity to histamine H 1 receptors has been identified as a main contributor for weight gain/obesity This study therefore investigated whether combined treatment betahistine (a receptor agonist and 3 antagonist) could reduce the body weight/obesity induced by olanzapine. Female Sprague Dawley rats were treated orally with...
Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it associated with troublesome metabolic side-effects, particularly body weight gain obesity. The antagonistic affinity to histamine H1 receptors (H1R) drugs has been identified as main contributors gain/obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment betahistine (an H1R agonist H3R antagonist) olanzapine (O+B) reduced (−45%)...
Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant or refractory schizophrenia. The gold standard for treatment is clozapine. However, a significant number patients cease clozapine therapy; therefore this study explores patient's motives cessation.The cessation and duration retrospective database 151 schizo-affective disorder who had ceased once more were reviewed, the coded. general non-compliance, own decision, medical, poor response other. In...
Introduction: Bipolar affective disorder (BPAD) is a severe mental illness causing significant problems in the lives of individuals with and those who care for them as well are. Most time people are taken by health professionals, while little priority given to their caregivers. There numerous studies India attempting understand impact on caregivers faced persons BPAD. Methods: The study aimed assess family caregivers' stress burden among BPAD at tertiary center Dharwad, India. Descriptive...
Background: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cognitive symptoms of schizophrenia can cause serious metabolic side-effects. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity neuroprotective properties. The aim this study was to examine whether liraglutide prevents weight gain/hyperglycaemia side-effects deficits when co-administered from commencement clozapine treatment. Methods: Rats were...
<b>Background:</b> With the advent of newer antipsychotic drugs, side effects such as sexual dysfunction have been a major contributor toward treatment compliance. There are only few studies that compared different atypical agents regarding dysfunction. We not come across any data in this area on Indian population. <br><b> Aims:</b> To determine and compare frequency associated with risperidone, olanzapine, quetiapine, among patients clinically stable schizophrenia.<br><b> Settings...
Refractory schizophrenia (SZ) affects approximately 30% of people with SZ. Clozapine (CLZ) is the gold standard treatment; however, there are still patients who non-responsive or partially responsive to treatment. Although a lack evidence exists in reality, these treated combination agents addition CLZ. Therefore, this article reviews prevalence augmentation CLZ additional agents.This study was cross-sectional; physicians region Australia May 2011 were contacted provide details their on and...
Abstract Background To examine real-world patterns of antipsychotic use in patients with schizophrenia Australia. Methods This retrospective cohort analysis was conducted using the Australian Commonwealth Department Human Services Pharmaceutical Benefits Scheme (PBS) 10% sample data. Included data were for aged 16-years or older who initiated treatment first time a PBS-reimbursed medication between July 2013 and September 2017. Patterns usage summarised descriptively. Differences prescribing...